USMIRC News 4th issue 9-2-2025

Talquetamab & Dysgeusia!!!

Infections with Bispecific Antibodies in Hematologic Malignancies!

USMIRC: A Catalyst for Equitable Access and Education

USMIRC International

USMIRC social media selected posts.

RedirecTT-1 Study - Talquetamab plus Teclistamab for Relapsed/Refractory Multiple Myeloma